Lunai Bioworks
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Lunai Bioworks and buy or sell other stocks, ETFs, and their options commission-free!About RENB
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21.
CEODavid Weinstein
CEODavid Weinstein
Employees29
Employees29
HeadquartersLos Angeles, California
HeadquartersLos Angeles, California
Founded2011
Founded2011
Employees29
Employees29
RENB Key Statistics
Market cap32.92M
Market cap32.92M
Price-Earnings ratio-0.14
Price-Earnings ratio-0.14
Dividend yield—
Dividend yield—
Average volume490.96K
Average volume490.96K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$20.40
52 Week high$20.40
52 Week low$0.81
52 Week low$0.81
Stock Snapshot
With a market cap of 32.92M, Lunai Bioworks(RENB) trades at $1.42. The stock has a price-to-earnings ratio of -0.14.
On 2025-12-15, Lunai Bioworks(RENB) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Lunai Bioworks(RENB) stock has reached 0, versus its average volume of 490.96K.
The stock's 52-week range extends from a low of $0.81 to a high of $20.40.
The stock's 52-week range extends from a low of $0.81 to a high of $20.40.
People also own
Based on the portfolios of people who own RENB. This list is generated using Robinhood data, and it’s not a recommendation.